Summary & Overview
CPT 0596U: Precivity–ApoE™ APOE Proteotype by LC-MS/MS
CPT code 0596U designates the proprietary Precivity–ApoE™ blood test from C2N Diagnostics LLC, a PLA code used for laboratory measurement of APOE protein isoforms (APOE2, APOE3, APOE4) via liquid chromatography–tandem mass spectrometry and summarized as an APOE proteotype. The code matters nationally because APOE genotype and proteotype information is increasingly relevant to Alzheimer’s disease risk assessment and patient stratification for clinical care and research.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find context on the clinical purpose of the test, expected service setting, and the nature of PLA codes. The publication provides benchmarks and coverage landscape commentary for major national payers, highlights policy themes affecting proprietary laboratory tests, and summarizes clinical considerations for APOE proteotype reporting. Data not available in the input is noted where specific payer policies, rate benchmarks, or billing line items are required.
This summary is intended for clinicians, laboratory billing specialists, and policy analysts seeking a concise overview of CPT code 0596U, its clinical relevance, and the payer coverage environment at a national level.
Billing Code Overview
CPT code 0596U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to the Precivity–ApoE™ test manufactured by C2N Diagnostics LLC. This blood-based laboratory test quantifies three isoforms of the APOE protein — APOE2, APOE3, and APOE4 — using liquid chromatography coupled with tandem mass spectrometry. Results are summarized as an APOE proteotype to assist in assessing a person’s genetic profile related to Alzheimer’s disease.
Service type: Laboratory testing — proprietary APOE proteotype analysis using LC-MS/MS
Typical site of service: Clinical laboratory or diagnostic testing facility (blood draw performed in ambulatory clinic or laboratory setting)
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient with progressive memory decline is evaluated in a neurology clinic to clarify Alzheimer's disease risk and aid in counseling and care planning. After clinical assessment including cognitive testing and brain imaging, the neurologist orders the Precivity–ApoE™ blood test (0596U) to determine the APOE proteotype (APOE2, APOE3, APOE4 isoforms) using liquid chromatography–tandem mass spectrometry. A phlebotomy draw is performed in the outpatient clinic or an affiliated laboratory; the specimen is shipped per the manufacturer's instructions to C2N Diagnostics LLC. Results reporting includes the APOE proteotype and interpretation to assist in assessing genetic risk for Alzheimer’s disease and to inform prognosis, eligibility for specific therapies or clinical trials, and family counseling. Typical sites of service are outpatient neurology clinics, memory centers, or independent clinical laboratories performing the send-out test.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work, time, or complexity of specimen collection or coordination substantially exceeds typical requirements for the test. |
52 |